Does the media refer more to STOK or PRTA?

In the previous week, Stoke Therapeutics had 2 more articles in the media than Prothena. MarketBeat recorded 4 mentions for Stoke Therapeutics and 2 mentions for Prothena. Stoke Therapeutics' average media sentiment score of 0.74 beat Prothena's score of 0.22 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, PRTA or PGEN?

Precigen is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 46.83 -$244.09M -$2.82 N/A Precigen $9.68M 182.31 -$250.64M -$1.18 N/A

Is PRTA or PGEN more profitable?

Prothena has a net margin of -260.92% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Prothena's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -260.92% -43.44% -36.87% Precigen -646.99% 717.50% 58.48%

Does the media refer more to PRTA or PGEN?

In the previous week, Prothena had 1 more articles in the media than Precigen. MarketBeat recorded 2 mentions for Prothena and 1 mentions for Precigen. Precigen's average media sentiment score of 1.01 beat Prothena's score of 0.22 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, PRTA or ZYME?

Zymeworks has higher revenue and earnings than Prothena. Zymeworks is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 46.83 -$244.09M -$2.82 N/A Zymeworks $105.96M 16.67 -$81.13M -$1.37 N/A

Is PRTA or ZYME more profitable?

Zymeworks has a net margin of -126.92% compared to Prothena's net margin of -260.92%. Zymeworks' return on equity of -37.97% beat Prothena's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -260.92% -43.44% -36.87% Zymeworks -126.92% -37.97% -25.31%

Does the media favor PRTA or ZYME?

In the previous week, Zymeworks had 5 more articles in the media than Prothena. MarketBeat recorded 7 mentions for Zymeworks and 2 mentions for Prothena. Zymeworks' average media sentiment score of 0.90 beat Prothena's score of 0.22 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zymeworks 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRTA or BHC more profitable?

Bausch Health Cos has a net margin of -11.47% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Prothena -260.92% -43.44% -36.87% Bausch Health Cos -11.47% -2,922.77% 5.63%

Prothena (PRTA) Competitors

$8.66 +0.19 (+2.24%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$8.60 -0.06 (-0.67%)

As of 07/17/2026 07:55 PM Eastern

Compare

PRTA vs. STOK, GENB, PGEN, ZYME, and BHC

Should you buy Prothena stock or one of its competitors? MarketBeat compares Prothena with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prothena include Stoke Therapeutics (STOK), Generate Biomedicines (GENB), Precigen (PGEN), Zymeworks (ZYME), and Bausch Health Cos (BHC). These companies are all part of the "pharmaceutical products" industry.

How does Prothena compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Prothena has a net margin of -260.92% compared to Stoke Therapeutics' net margin of -529.20%. Prothena's return on equity of -43.44% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Prothena	-260.92%	-43.44%	-36.87%

Stoke Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market. Comparatively, Prothena has a beta of -0.31, indicating that its stock price is 131% less volatile than the broader market.

97.1% of Prothena shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Stoke Therapeutics has higher revenue and earnings than Prothena. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	9.81	-$6.89M	-$2.81	N/A
Prothena	$9.68M	46.83	-$244.09M	-$2.82	N/A

In the previous week, Stoke Therapeutics had 2 more articles in the media than Prothena. MarketBeat recorded 4 mentions for Stoke Therapeutics and 2 mentions for Prothena. Stoke Therapeutics' average media sentiment score of 0.74 beat Prothena's score of 0.22 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Stoke Therapeutics presently has a consensus price target of $43.00, suggesting a potential upside of 48.02%. Prothena has a consensus price target of $23.75, suggesting a potential upside of 174.25%. Given Prothena's higher probable upside, analysts clearly believe Prothena is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Prothena beats Stoke Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Prothena compare to Generate Biomedicines?

Prothena (NASDAQ:PRTA) and Generate Biomedicines (NASDAQ:GENB) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Generate Biomedicines has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Generate Biomedicines' return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Generate Biomedicines	N/A	N/A	N/A

Prothena presently has a consensus target price of $23.75, suggesting a potential upside of 174.25%. Generate Biomedicines has a consensus target price of $25.40, suggesting a potential upside of 87.32%. Given Prothena's higher probable upside, analysts plainly believe Prothena is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Generate Biomedicines has higher revenue and earnings than Prothena. Generate Biomedicines is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	46.83	-$244.09M	-$2.82	N/A
Generate Biomedicines	$30.30M	57.37	-$137.17M	-$1.07	N/A

In the previous week, Prothena had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 2 mentions for Prothena and 0 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 1.00 beat Prothena's score of 0.22 indicating that Generate Biomedicines is being referred to more favorably in the news media.

Company	Overall Sentiment
Prothena	Neutral
Generate Biomedicines	Positive

97.1% of Prothena shares are held by institutional investors. 10.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Generate Biomedicines beats Prothena on 10 of the 16 factors compared between the two stocks.

How does Prothena compare to Precigen?

Prothena (NASDAQ:PRTA) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Prothena has a net margin of -260.92% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Precigen	-646.99%	717.50%	58.48%

97.1% of Prothena shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Prothena had 1 more articles in the media than Precigen. MarketBeat recorded 2 mentions for Prothena and 1 mentions for Precigen. Precigen's average media sentiment score of 1.01 beat Prothena's score of 0.22 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prothena has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market. Comparatively, Precigen has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Precigen is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	46.83	-$244.09M	-$2.82	N/A
Precigen	$9.68M	182.31	-$250.64M	-$1.18	N/A

Prothena presently has a consensus price target of $23.75, indicating a potential upside of 174.25%. Precigen has a consensus price target of $12.50, indicating a potential upside of 152.53%. Given Prothena's stronger consensus rating and higher possible upside, equities analysts clearly believe Prothena is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Prothena beats Precigen on 9 of the 16 factors compared between the two stocks.

How does Prothena compare to Zymeworks?

Prothena (NASDAQ:PRTA) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Zymeworks has higher revenue and earnings than Prothena. Zymeworks is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	46.83	-$244.09M	-$2.82	N/A
Zymeworks	$105.96M	16.67	-$81.13M	-$1.37	N/A

Zymeworks has a net margin of -126.92% compared to Prothena's net margin of -260.92%. Zymeworks' return on equity of -37.97% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Zymeworks	-126.92%	-37.97%	-25.31%

97.1% of Prothena shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 10.4% of Prothena shares are held by company insiders. Comparatively, 33.5% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Prothena has a beta of -0.31, indicating that its stock price is 131% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

In the previous week, Zymeworks had 5 more articles in the media than Prothena. MarketBeat recorded 7 mentions for Zymeworks and 2 mentions for Prothena. Zymeworks' average media sentiment score of 0.90 beat Prothena's score of 0.22 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zymeworks	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prothena presently has a consensus target price of $23.75, suggesting a potential upside of 174.25%. Zymeworks has a consensus target price of $37.33, suggesting a potential upside of 54.33%. Given Prothena's higher possible upside, equities analysts clearly believe Prothena is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Zymeworks beats Prothena on 12 of the 16 factors compared between the two stocks.

How does Prothena compare to Bausch Health Cos?

Prothena (NASDAQ:PRTA) and Bausch Health Cos (NYSE:BHC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Bausch Health Cos has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	46.83	-$244.09M	-$2.82	N/A
Bausch Health Cos	$10.27B	0.18	$157M	-$3.24	N/A

Bausch Health Cos has a net margin of -11.47% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

In the previous week, Prothena had 2 more articles in the media than Bausch Health Cos. MarketBeat recorded 2 mentions for Prothena and 0 mentions for Bausch Health Cos. Prothena's average media sentiment score of 0.22 beat Bausch Health Cos' score of 0.00 indicating that Prothena is being referred to more favorably in the media.

Company	Overall Sentiment
Prothena	Neutral
Bausch Health Cos	Neutral

Prothena currently has a consensus price target of $23.75, suggesting a potential upside of 174.25%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 64.78%. Given Prothena's stronger consensus rating and higher probable upside, equities research analysts plainly believe Prothena is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Prothena has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

97.1% of Prothena shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Prothena beats Bausch Health Cos on 10 of the 17 factors compared between the two stocks.

Get Prothena News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTA vs. The Competition

Export

Metric	Prothena	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$453.38M	$3.69B	$6.87B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	-3.07	21.03	27.25	23.92
Price / Sales	46.83	167.28	513.66	89.44
Price / Cash	N/A	154.08	52.99	60.41
Price / Book	1.66	8.26	10.69	6.18
Net Income	-$244.09M	$23.83M	$3.59B	$332.29M
7 Day Performance	-6.28%	-3.47%	-2.20%	-2.05%
1 Month Performance	-3.02%	2.69%	1.63%	-2.18%
1 Year Performance	38.34%	45.93%	25.64%	17.67%

Prothena Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTA Prothena	2.7442 of 5 stars	$8.66 +2.2%	$23.75 +174.2%	+38.3%	$453.38M	$9.68M	N/A	130
STOK Stoke Therapeutics	2.3256 of 5 stars	$29.18 -1.0%	$42.00 +43.9%	+119.7%	$1.82B	$184.42M	N/A	100
GENB Generate Biomedicines	2.962 of 5 stars	$14.15 -0.9%	$25.40 +79.6%	N/A	$1.82B	$30.30M	N/A	312	Positive News Gap Down
PGEN Precigen	2.7569 of 5 stars	$5.09 -1.6%	$12.50 +145.8%	+181.3%	$1.82B	$9.68M	N/A	190	Positive News
ZYME Zymeworks	3.143 of 5 stars	$24.69 -1.0%	$37.33 +51.2%	N/A	$1.80B	$105.96M	N/A	460

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTA) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prothena (PRTA) Competitors

PRTA vs. STOK, GENB, PGEN, ZYME, and BHC

How does Prothena compare to Stoke Therapeutics?

Summary

How does Prothena compare to Generate Biomedicines?

Summary

How does Prothena compare to Precigen?

Summary

How does Prothena compare to Zymeworks?

Summary

How does Prothena compare to Bausch Health Cos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA vs. The Competition

Prothena Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prothena (PRTA) Competitors

PRTA vs. STOK, GENB, PGEN, ZYME, and BHC

How does Prothena compare to Stoke Therapeutics?

Is STOK or PRTA more profitable?

Which has more volatility and risk, STOK or PRTA?

Do institutionals and insiders hold more shares of STOK or PRTA?

Which has better valuation & earnings, STOK or PRTA?

Does the media refer more to STOK or PRTA?

Do analysts prefer STOK or PRTA?

Summary

How does Prothena compare to Generate Biomedicines?

Is PRTA or GENB more profitable?

Do analysts recommend PRTA or GENB?

Which has better valuation and earnings, PRTA or GENB?

Does the media refer more to PRTA or GENB?

Do institutionals and insiders hold more shares of PRTA or GENB?

Summary

How does Prothena compare to Precigen?

Is PRTA or PGEN more profitable?

Do institutionals & insiders believe in PRTA or PGEN?

Does the media refer more to PRTA or PGEN?

Which has more risk & volatility, PRTA or PGEN?

Which has preferable earnings and valuation, PRTA or PGEN?

Do analysts prefer PRTA or PGEN?

Summary

How does Prothena compare to Zymeworks?

Which has preferable valuation & earnings, PRTA or ZYME?

Is PRTA or ZYME more profitable?

Do institutionals and insiders hold more shares of PRTA or ZYME?

Which has more volatility and risk, PRTA or ZYME?

Does the media favor PRTA or ZYME?

Do analysts recommend PRTA or ZYME?

Summary

How does Prothena compare to Bausch Health Cos?

Which has stronger earnings and valuation, PRTA or BHC?

Is PRTA or BHC more profitable?

Does the media favor PRTA or BHC?

Do analysts recommend PRTA or BHC?

Which has more volatility & risk, PRTA or BHC?

Do insiders and institutionals hold more shares of PRTA or BHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA vs. The Competition

Prothena Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools